Screener
Vertex Pharmaceuticals VRTX CASGEVY — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's CASGEVY — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported CASGEVY — product revenues, net of $76.4M in Q2 2026.
- How has Vertex Pharmaceuticals's CASGEVY — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's CASGEVY — product revenues, net increased by 151.3% year-over-year, from $30.4M to $76.4M.
- What does CASGEVY — product revenues, net mean?
- This metric represents the total net revenue generated from the sale of a specific gene-editing therapy product after accounting for returns, discounts, and rebates. It serves as a primary indicator of the commercial adoption and market penetration of the company's advanced therapeutic portfolio. Tracking this revenue stream is essential for evaluating the growth trajectory of the company's diversification strategy beyond its core small-molecule franchise.
Ask your AI about Vertex Pharmaceuticals's casgevy — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude